2月5日，复宏汉霖（股票代码：2696.HK）宣布了一项重大突破：其自主研发的抗PD-1单抗H药——汉斯状®（斯鲁利单抗，欧洲商品名：Hetronifly®）正式获得欧盟委员会（European Commission， EC）的批准，联合卡铂和依托泊苷用于广泛期小细胞肺癌（ES-SCLC）成人患者的一线治疗。这一里程碑式的成就标志着H药成为首个且唯一在欧盟获批上市用于广泛期小细胞肺癌治疗的抗PD-1单抗，为全球小细胞肺癌患者带来了新的治疗曙光。
复宏汉霖执行董事、首席执行官朱俊博士表示：“H药在欧盟获批上市，标志着复宏汉霖在惠及全球患者的进程中再进一步。这一批准不仅进一步印证了我们在创新药物研发与国际化布局上的领先能力，也为欧洲乃至全球广泛期小细胞肺癌患者带来了新的治疗希望。未来，我们将继续以全球临床需求为导向，与合作伙伴携手提高先进疗法的可及性，共同为改变患者生命而努力。”
关键词阅读：复宏汉霖
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.